Research programme: anticancer therapeutics - Medpacto

Drug Profile

Research programme: anticancer therapeutics - Medpacto

Alternative Names: TEW 0201; UAI 201

Latest Information Update: 20 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator YOUAI
  • Developer MedPacto
  • Class Small molecules; Sulfonamides
  • Mechanism of Action Proto oncogene protein b raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Colorectal cancer; Malignant melanoma

Most Recent Events

  • 01 Jul 2013 Medpacto acquires TEW 0201 from Youai
  • 01 Jul 2013 Preclinical trials in Cancer in South Korea (unspecified route)
  • 01 Jul 2013 Preclinical trials in Colorectal cancer in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top